AU Patent

AU2005311652B2 — Pharmaceutical formulation of carboxamide HIV integrase inhibitors containing a release rate controlling composition

Assigned to Merck Sharp and Dohme LLC · Expires 2010-12-02 · 15y expired

What this patent protects

Patent listed against raltegravir-potassium.

Drugs covered by this patent

raltegravir-potassium (RALTEGRAVIR POTASSIUM)

Patent Metadata

Patent number: AU2005311652B2
Jurisdiction: AU
Classification: —
Expires: 2010-12-02
Drug substance claim: No
Drug product claim: No
Assignee: Merck Sharp and Dohme LLC
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.